| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | VERVE-201 (ANGPTL3 Program) Refractory hypercholesterolemia (patients with high LDL-C despite maximally tolerated standard of care) and homozygous familial hypercholesterolemia (HoFH) populations as specified in company materials | Phase 1b | — | CRISPR-Based Gene Editing Therapies | - | ||
Phase 1b data readout example | VERVE-201 (ANGPTL3 Program) Refractory hypercholesterolemia (patients with high LDL-C despite maximally tolerated standard of care) and homozygous familial hypercholesterolemia (HoFH) populations as specified in company materials | Phase 1b | — | CRISPR-Based Gene Editing Therapies | - | ||
Phase 1b data readout example | VERVE-201 (ANGPTL3 Program) Refractory hypercholesterolemia (patients with high LDL-C despite maximally tolerated standard of care) and homozygous familial hypercholesterolemia (HoFH) populations as specified in company materials | Phase 1b | — | CRISPR-Based Gene Editing Therapies | - |
Recent Updates
Recently added Catalysts
Verve Therapeutics, Inc.$11.13
-0.01 (-0.09%)
D 32Pipeline Score Overvalued Biotech · Clinical
Market Cap
992.16 M
EPS
-2.11
P/E Ratio
-
Value Trade
114.94 M
1.09 %
Week
-0.18 %
1 Month
94.58 %
3 Month
39.3 %
6 Month
-62.9 %
5 Year
-62.9 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
10.31 M
52 Week Range
2.86 - 11.41
% held by Insiders
26.23 %
% held by Institutions
73.69 %
Enterprise Value
563.72 M
Total Shares
89.14 M
Short %
27.37 %
Float Shares
65.76 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D32
Pipeline Score $177M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 40%
Micro Cap (rank 544 of 905)
Percentile RankVerve Therapeutics, Inc. faces pipeline headwinds (32/100), with $621M risk-adjusted pipeline value, led by VERVE-201 in Hypercholesterolemia (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VERVE-201 Small molecule | Hypercholesterolemia | Phase 1 | NCT06451770 | 14% | $515M | RECRUITING | 36 | STALLED | D (37) | Dec 1, 2027 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VERV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Verve Therapeutics, Inc. (VERV) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
VERV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VERV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VERV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VERV Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VERV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How VERV ranks across every disease it competes inCompetitive Position is a premium feature
See how VERV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial